Kidney care is also important for diabetic patients

SGLT-2 inhibitors solve this problem

Jardiance's clinical trial ended early

Major US, European and domestic academic societies recommend SGLT-2 inhibitors to guidelines

SGLT-2 inhibitors, which have obtained indications for chronic kidney disease, are emerging as the mainstay of chronic disease management along with diabetes.

 

According to data from the Korean Diabetes Association, the rate of kidney disease accompanied by type 2 diabetes patients in Korea was about 30%, and one in three diabetes patients in Korea had renal function abnormalities.

 

Studies have also shown that diabetes (40%) is the most common cause of end-stage kidney disease.

 

Diabetes patients have an average annual glomerular filtration rate (eGFR) decrease about twice as quickly as those without diabetes, and the 10-year neoplasia rate for diabetic patients is very low at 40%.

 

Effectiveness of SGLT-2 inhibitors Forxiga, the first diabetic drug in the SGLT-2 inhibition mechanism to obtain an indication for chronic kidney disease, is also drawing attention from domestic medical staff.

 

Forxiga confirmed the benefits of kidney disease in type 2 diabetic patients through a study of DECLARE-TIMI 58.

 

In Forxiga of the DECLARE study, the secondary renal complex evaluation index (decreased by more than 40% eGFR, death from terminal kidney disease, kidney or cardiovascular disease) was 4.3% lower than placebo.

 

The kidney subanalysis of the same clinical trial showed a continuous decrease in eGFR compared to placebo of less than 60 ml/min1.73 m2 by more than 40%, and a 47% reduction in the risk of death from terminal kidney disease or kidney disease.

 

Forxiga confirmed benefits for patients with chronic kidney disease, regardless of diabetes.

 

Jardiance is currently in the process of obtaining a kidney disease indication in the United States.

 

This drug was confirmed to be effective through EMPA-KIDNEY research.

 

The study will be discontinued early according to the recommendation of an independent data monitoring committee while meeting the criteria for positive efficacy.

 

#Sb Society Guidelines also emphasize importance Several domestic and foreign societies first recommend SGLT-2 inhibitors to type 2 diabetes patients with chronic kidney disease in treatment guidelines, emphasizing the importance of integrated management of diabetes and kidney disease.

 

The Korean Diabetes Association recommended that treatments including SGLT-2 inhibitors that have proven cardiovascular and kidney benefits should be considered first if albuminuria exists or the estimated glomerular filtration rate decreases in the 2021 Diabetes Care Guidelines.

 

The American Diabetes Association recommended the use of SGLT-2 inhibitors that demonstrated benefits from heart failure or kidney disease in patients with heart failure or chronic kidney disease in the "2022 Diabetes Guidelines".

 

The European Association for the Study of Diabetes and European Society of Cardiology also recommended SGLT-2 inhibitors as drugs to reduce the progression of diabetic nephropathy in the area of chronic kidney disease management in the "2019 Guidelines for Diabetes, Prediabetes and Cardiology".

 

The KDIGO also recommended combination therapy with metformin and SGLT-2 inhibitors as the primary treatment along with lifestyle correction such as physical activity, diet, and weight loss in patients with chronic kidney disease with glomerular filtration rate of 30ml/min/1.73m2.

 

Kim Dae Joong Professor of Endocrinology at Ajou University Hospital said, "In the long run, exposure to high blood sugar can cause glomerular damage, and proteinuria can occur from a relatively early stage in diabetic patients, so albumin excretion in urine should be measured annually.

 

It is important to evaluate the glomerular filtration rate to determine the degree of abnormalities in new functions," he advised.